Quantitative bremsstrahlung SPECT imaging: attenuation-corrected activity determination
- PMID: 8014685
Quantitative bremsstrahlung SPECT imaging: attenuation-corrected activity determination
Abstract
Bremsstrahlung SPECT imaging and activity quantitation have been performed using 32P-chromic phosphate.
Methods: Attenuation correction was applied to the reconstructed transverse SPECT slices using a commercially available first-order postprocessing algorithm. The patient's body contour was defined through the use of four externally placed sources and attenuation correction was then performed with an experimentally determined effective linear attenuation coefficient for 32P. Phantom studies were performed to determine the activity needed in the four external sources and also to validate absolute activity analysis on the reconstructed SPECT slices. A computer algorithm was written to facilitate ROI activity determination based on a fixed threshold method. Four cancer patients enrolled in clinical Phase I protocols were injected with 2.5 million particles of macro-aggregated albumin followed by colloidal 32P-chromic phosphate by direct interstitial injection into the tumor-bearing region under CT guidance. The in vivo 32P activity distribution was restricted to a small volume with minimal background activity. SPECT images were obtained in these patients and the activity of 32P present in the tumors was calculated from their attenuation-corrected reconstructed SPECT slices.
Results: The effective linear attenuation coefficient for 32P was determined to be 0.13 cm-1. A fixed 39% threshold was best for activity calculation since it provided the best correlation between known and measured activity levels in the phantom. The calculated activities were within 16.9% of the actual activities in the patients studied.
Conclusion: Accurate quantitative bremsstrahlung SPECT imaging with a commercially available postprocessing attenuation correction algorithm can be performed in a clinical setting.
Similar articles
-
Quantitative bremsstrahlung single photon emission computed tomographic imaging: use for volume, activity, and absorbed dose calculations.Int J Radiat Oncol Biol Phys. 1995 Feb 15;31(4):953-8. doi: 10.1016/0360-3016(94)00464-1. Int J Radiat Oncol Biol Phys. 1995. PMID: 7860411
-
Body contour determination and validation for bremsstrahlung SPECT imaging.J Nucl Med. 1996 Mar;37(3):495-7. J Nucl Med. 1996. PMID: 8772654 Clinical Trial.
-
Clinical fusion of three-dimensional images using Bremsstrahlung SPECT and CT.J Nucl Med. 1997 Feb;38(2):319-24. J Nucl Med. 1997. PMID: 9025762
-
Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system.J Nucl Med. 2005 May;46(5):868-77. J Nucl Med. 2005. PMID: 15872362 Clinical Trial.
-
Quantitative accuracy of clinical 99mTc SPECT/CT using ordered-subset expectation maximization with 3-dimensional resolution recovery, attenuation, and scatter correction.J Nucl Med. 2010 Jun;51(6):921-8. doi: 10.2967/jnumed.109.071571. Epub 2010 May 19. J Nucl Med. 2010. PMID: 20484423
Cited by
-
Comparison of 90Y SIRT predicted and delivered absorbed doses using a PSF conversion method.Phys Med. 2021 Sep;89:1-10. doi: 10.1016/j.ejmp.2021.07.026. Epub 2021 Jul 30. Phys Med. 2021. PMID: 34339928 Free PMC article.
-
Quantitative Imaging of Alpha-Emitting Therapeutic Radiopharmaceuticals.Nucl Med Mol Imaging. 2019 Jun;53(3):182-188. doi: 10.1007/s13139-019-00589-8. Epub 2019 Feb 18. Nucl Med Mol Imaging. 2019. PMID: 31231438 Free PMC article. Review.
-
Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S57-68. doi: 10.1007/s00259-011-1771-7. Epub 2011 Mar 11. Eur J Nucl Med Mol Imaging. 2011. PMID: 21484382 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources